Better Therapeutics to Present Phase 2 Data in Type 2 Diabetes at Endocrine 2020

Share Article

Study participants lowered HbA1c -1.0% over 12 weeks of treatment.

“We are encouraged to see such a strong efficacy signal in a diverse group of patients with long-standing diabetes.” Dr. Mark Berman, Chief Medical Officer

Better Therapeutics, a developer of prescription digital therapeutics for the treatment of cardiometabolic diseases, today announced an upcoming poster presentation at the Endocrine 2020 conference. The presentation will include data from a pilot study of Better’s software-only prescription digital therapeutic in patients with type 2 diabetes. The conference will take place on March 28-31, at San Francisco’s Moscone Center.

The pilot studied 74 participants with type 2 diabetes and a baseline HbA1c ≥ 7%. Diabetes is defined by an HbA1c value of 6.5% or higher. In addition, study participants had a mean age of 55.2 years, baseline BMI of 34.7 kg/m2, 10.6 years since diagnosis of type 2 diabetes and 72% were female.

Here are the details of the upcoming poster presentation:

Poster Title: A Software Application Delivering Behavioral Therapy Improved Glycemic Control in Adults With Type 2 Diabetes
Poster Board #: SAT-LB120
Date & Time: Saturday, March 28, 2020, 1:00 - 3:00 PM

A study abstract of preliminary results has been included in the conference guide, and will be published in the Journal of the Endocrine Society and on the Better Therapeutics website later this month. Highlights of the pilot study include:

  • Mean reduction in fasting blood glucose of 21.9 mg/dL (approximately -1.0% HbA1c) over an average of 73 days between baseline and ending values.
  • Larger improvements in fasting blood glucose are seen in participants with higher use of the behavioral therapy. An improvement of -32.0 mg/dL was observed in the highest tertile of use compared to -14.3 mg/dL in the lowest tertile.
  • Participants used the digital therapeutic 4.4 days a week on average, and spent an average of 6 minutes during each use.

Next, the company will conduct an open-label, multi-site, randomized, controlled, parallel-group trial of its digital therapeutic for treating type 2 diabetes and submit the results as the basis of its premarket submission to the U.S. Food and Drug Administration (FDA).

About Better Therapeutics
Better is developing prescription digital therapeutics (PDTs) for the treatment of diabetes, heart disease, and other chronic conditions. Today, drugs are used to treat the effects of these diseases while leaving the behaviors that cause them in place. Better's PDTs treat and often reverse disease by changing behaviors using nutritional CBT, a novel form of digitally-delivered behavioral therapy. Better’s PDTs are clinically-validated, FDA-regulated software applications intended to be prescribed and reimbursed like traditional prescription medicines.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lauren Burns
@Better_TX
Follow >
Visit website